Objectif
Adverse drug reactions (Adds) are important causes of morbidity and mortality, and are under strong genetic influence. Identifying genetic variants that influence susceptibility to Adds has obvious practical applications, and will contribute to understanding of the molecular basis of adverse drug reactions. Research in this area is hampered by the lack of a resource in which to study genetic determinants of susceptibility to Adds. As most adverse reactions are rare, a case-control study is the only feasible design in which to study genetic associations. To obtain adequate numbers of cases of each of the Adds under study, a multicoated European collaboration is necessary as no single country will generate enough cases of any given ADR within a reasonable time. We propose to establish a freely shared resource consisting of clinical data and DNA samples from cases of Adds, together with a control group.